Busch Matthew C. 4
4 · AMGEN INC · Filed Feb 20, 2026
Research Summary
AI-generated summary of this filing
Amgen VP Matthew C. Busch Sells 1,000 Shares
What Happened Matthew C. Busch, Vice President, Finance & Chief Accounting Officer of Amgen Inc. (AMGN), sold 1,000 shares of Amgen common stock in an open-market transaction on February 19, 2026. The shares were sold at $375.79 per share for gross proceeds of $375,790. This was a sale (not a purchase or exercise) and thus is typically considered routine insider selling rather than an explicit positive signal.
Key Details
- Transaction date and price: 2026-02-19 — 1,000 shares sold at $375.79 per share (total $375,790).
- Filing date / timeliness: Form 4 filed 2026-02-20 for the 2026-02-19 transaction (filed the next day).
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Footnote: The filing notes 60 Dividend Equivalents (DEs) are included; DEs are credited to unvested RSUs and are paid in shares on a one-to-one basis per the vesting schedule, with cash for any fractional share.
Context This was an open-market sale (code S). Sales by officers can be routine (cash needs, diversification, tax obligations, or portfolio rebalancing) and do not by themselves indicate a change in company outlook. No option exercises, gifts, or tax-withholding events were reported in this transaction.
Insider Transaction Report
- Sale
Common Stock
[F1]2026-02-19$375.79/sh−1,000$375,790→ 3,423 total
Footnotes (1)
- [F1]These shares include 60 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.